Competing interests
The ADVENT study was sponsored by grant 2013BAI09B12 and 2015BAI12B13 from National Science and Technology Infrastructure Program, grant 2021JC003 from the Natural Science Foundation of Hunan Province, and grant from AstraZeneca Investment (China) Co., Ltd. Z.Zho. reports grants from AstraZeneca and personal fees from Eli Lilly, Boehringer Ingelheim, Sanofi-Aventis, Merck, AstraZeneca, and Novo Nordisk. R.D.L. is on the advisory board of Diamyd. X.Y. reports grants from National Science and Technology Infrastructure Program and personal fees from Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi-Aventis. X.L. reports personal fees from Eli Lilly, Boehringer Ingelheim, Sanofi-Aventis, Merck, AstraZeneca, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Z.Zho., X.Y. and L.X. received honoraria for lectures from AstraZeneca company, but these were provided outside the submitted work.